Advocate, Courtyard Attorneys, 47/1345, MIG Adarsh Nagar, Worli, Mumbai 400 030 INDIA.
Independent Journalist, 8, Seadoll, 54 Chimbai Road, Bandra West, Mumbai 400 050 INDIA.
Indian J Med Ethics. 2024 Jul-Sep;IX(3):175-179. doi: 10.20529/IJME.2024.041.
In April 2024, in a class action suit for compensation to families of persons suffering injury or death after vaccination with AstraZeneca's (AZ) Covid-19 vaccine [1], the manufacturer admitted in a UK court that the Oxford-AZ Covid-19 vaccine could cause a rare and potentially fatal blood clotting disorder ("thrombosis with thrombocytopenia syndrome" or TTS, which when triggered by a vaccine is called "vaccine induced thrombocytopenia and thrombosis, or VITT) [2]. The AZ Covid-19 vaccine is a chimpanzee adenovirus vectored vaccine encoding the SARS-CoV2 spike protein (ChAdOx1-S) marketed under the names Covishield and Vaxzevria.
2024 年 4 月，在针对阿斯利康（AstraZeneca）COVID-19 疫苗接种后受伤或死亡的人员家属的集体诉讼中，制造商在英国法庭承认，牛津-阿斯利康 COVID-19 疫苗可能导致罕见且潜在致命的血液凝结障碍（“血栓性血小板减少综合征”或 TTS，当由疫苗引发时称为“疫苗诱导的血小板减少和血栓形成，或 VITT”）[2]。阿斯利康 COVID-19 疫苗是一种编码 SARS-CoV2 刺突蛋白的 chimpanzee 腺病毒载体疫苗（ChAdOx1-S），以 Covishield 和 Vaxzevria 的名称销售。
